A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD).

Project: Research

StatusActive
Effective start/end date8/01/1931/12/20